期刊文献+

高效液相色谱法测定血浆6-巯基嘌呤质量浓度及其药动学 被引量:4

Determination of 6-mercaptopurine in human plasma by HPLC and study on its pharmacokinetics
下载PDF
导出
摘要 目的:建立血浆中硫唑嘌呤的活性代谢物6-巯基嘌呤质量浓度测定的高效液相色谱分析方法,并研究了6-巯基嘌呤人体药动学。方法:6-巯基嘌呤血浆样品经乙腈沉淀蛋白并行萃取,进一步将有机层吹干富集药品。Hypersil C18柱(4.6mm×150mm,5μm),流动相为乙腈一水(含0.25%醋酸)(3:97),流速1.0mL·min^-1,柱温30℃,检测波长323nm。结果:6-巯基嘌呤在2~200μg·L^-1范围内线性关系良好(r=0.9997),血浆最低检测限度为2μg·L^-1。高、中、低质量浓度(200,50,5μg·L^-1,)的日内及日间RSD均小于8.52%,平均方法回收率分别为98.1%,101.6%和100.8%,平均提取回收率分别为90.2%,94.9%和91).90%。人体药动学研究表明,口服硫唑嘌呤后6-巯基嘌呤的药一时曲线符合一级吸收的一房室模型。结论:此法灵敏、专一、准确、精密、简便,适用于药动学研究及治疗药物质量浓度监测。 OBJECTIVE To establish an HPLC method for the determination of 6-mercaptopurine in human plasma,which is the active metabolite of azathioprine, and to study its pharmacokinetics in healthy volunteers. METHODS 6-Mercaptopurine was extracted from human plasma with acetonitrile after deproteinized,and then detected by Hypersil C18 column(4. 6 mm× 150mam, 5μm) with UV detector at 323 nm. The mobile phase consisted of acetonitrile-water(0. 25% acetic acid)(3:97) with a flow rate of 1.0 mLo min^-1. RESULTS The calibration curve was linear over the range of 2-200μg·L^-1 ( r = 0. 999 7) and the limit of quantitation was 2μg·L analytical recoveries were 98.1% The intra- and inter-assay coefficients of variation were less than 8. 52% at all level. The mean 1%, 101.6 % and 100. 8 %, respectively. The mean extraction recoveries were 90.2 %, 94. 9 % and 90.9%,respectively. The results showed the concentration-time curves of 6-MP were fitted to one-compartment model with first order absorption. CONCLUSION This method is sensitive, specific, accurate, precise and rapid, and is suitable for the pharmacokinetic study of 6-MP and therapeutic drug monitoring.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2007年第2期193-196,共4页 Chinese Journal of Hospital Pharmacy
关键词 硫唑嘌呤 6-巯基嘌呤 高效液相色谱法 血药质量浓度 药动学 azathioprine 6-mercaptopurine HPLC plasma concentration pharmacokinetics
  • 相关文献

参考文献6

  • 1张海涛,王坤杰,李幼平,高励,刘瑾,蔡羽嘉.肾移植术后骁悉与硫唑嘌呤抗排斥反应随机对照试验的系统评价[J].中国循证医学杂志,2004,4(2):79-91. 被引量:2
  • 2Sandborn WJ.Rational dosing of azathioprine and 6-mercaptopurine[J].Gut,2001,48(5):591-592.
  • 3Zins BJ,Sandborn WJ,McKinney JA,et al.A dose-ranging study of azathioprine pharmacokinetics after single-dose administration of a delayed-release oral formulation[J].J Clin Pharmacol,1997,37(1):38-46.
  • 4Escousse A,Guedon F,Mounie J,et al.6-Mercaptopurine pharmacokinetics after use of azathioprine in renal transplant recipients with intermediate or high thiopurine methyl transferase activity phenotype[J].J Pharm Pharmacol,1998,50 (11):1261-1266.
  • 5Collie-Duguid ES,Pritchard SC,Powrie RH,et al.The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations[J].Pharmacogenetics,1999,(1):37-42.
  • 6Gearry RB,Barclay ML.Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease[J].J Gastroenterol Hepatol,2005,20(8):1149-1157.

二级参考文献26

  • 1Neylan JE. Immunosupppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients [ J ].Transplantation, 1997; 64(9): 1277-1282
  • 2The U. S. Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection of primary cadaveric kidney transplants: status of the MYC 1866 study at 1 year[J]. Transplant Proc, 1997; 29(1-2): 348-349
  • 3Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized,double-blind, clinical studies in prevention of rejection [J ].Transplantion, 1997; 63(
  • 4The Tricontinental Mycophnolate Mofetil Rneal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation[J]. Transplantation, 1996; 61(7): 1029-1037
  • 5European Mycophenolate Mofetil Cooperative Study Group.Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroid for prevention of acute rejection[J]. Lancet, 1995; 345(8961): 1321-1325
  • 6Ahsan N, Johnson C, Gonwa T, Hallorax P, Stegall M,Hardy M, Metzger R, Shield C, Rocher L, Scandling J.Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after
  • 7Johnson C, Ahsan N, Gonwa T, Hallorax P, Stegall M,Hardy M, Metzger R, Shield C, Rocher L, Scandling J.Random trial of tacrolimus in combination with azathioprine or mycophenolate mofetil versus cyclosponne with mycophenolate mofetil after cadaveric kidne
  • 8Jirasiritham S, Sumethkul V, Mavichak V, Chalermsanyakom P. The treatment of chronic rejection with mycophenolate mofetil versus azathioprine in kidney transplantation [ J ].Transplant Proc, 2000; 32(7): 2040-2042
  • 9MathewTH. Ablinded, long-time, randomizedmulticenter study of mycophenolate mofetil in cadaveric renal transplantation: result at three years [ J ]. Transplantation,1998; 65(11): 1450-1454
  • 10Mendez R. FK 5 0 6 and mycophenolate mofetil in renal transplant recipients: six-month result of a multicenter,randomized dose ranging trial. Transplantation Proc, 1998; 30(4): 1287-1289

共引文献1

同被引文献26

  • 1郑洪,鞠火晃先,朱广华.双嘧达莫对胰腺癌细胞内抗肿瘤药物6-巯基嘌呤浓度的影响及6-巯基嘌呤的荧光分光光度法测定[J].分析试验室,2004,23(8):1-4. 被引量:4
  • 2赵丹华,訾言勤.流动注射化学发光增强法测定巯嘌呤的应用研究[J].分析试验室,2006,25(1):65-68. 被引量:10
  • 3卢琴,赵成安,刘春,徐洪伟,王伦,周运友.6-巯基嘌呤-H_2O_2-Cu^(2+)-NaOH体系荧光分光光度法测定6-巯基嘌呤的研究[J].分析科学学报,2007,23(1):33-36. 被引量:4
  • 4Teml A, Schaeffeler E, Herrlinger KR, et al. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmaeogenetieally guided dosing [ J ]. Clin Pharmacokinet, 2007 ;46 : 187 - 208.
  • 5Sahasranaman S, Howard D, Roy S. Clinical pharmacology and pharmacogenetics of thiopurines [ J ]. Eur J Clin Pharmacol, 2008 ; 64:753 - 767.
  • 6Zhang JP, Zhou SF, Chen X, et al. Determination of intraethnic differences in the polymorphisms of thiopurine S - methyltransferase in Chinese [J]. Clin Chim Acta, 2006;365:337 -341.
  • 7Zhou S. Clinical pharmacogenomics of thiopurine S - methyltransferase [J]. Curr Clin Pharmaco, 2006;1:119 -128.
  • 8Winter JW, Gaffney D, Shapiro D, et al. Assessment of thiopurine methyhransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease [ J]. Aliment Pharmacol Ther, 2007; 25: 1069 - 1077.
  • 9Sahasranaman S,Howard D,Roy S. Clinical Pharmacology and Pharmacogenetics of Thiopurines[J]. Eur J Clin Pharmacol, 2008.64(8): 753—767.
  • 10王汝龙,原正平.化工产品手册药物[M].北京:化学工业出版社.2000,278.

引证文献4

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部